November 18, 2026
Health news, explained with evidence
LIVE
JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities

Study Clarifies the Link Between Treatment Timing and Survival in Lymphoma

🧠 AI Analysis 2 min read 👁 7

Researchers analyzing data from 2,610 diffuse large B-cell lymphoma patients found that a shorter interval between diagnosis and treatment actually reflects underlying disease severity rather than causing poorer outcomes.

🧠AI Analysis

Key points

  • Analyzed data from 2,610 DLBCL patients using causal inference methods.
  • Initial univariable analysis linked faster treatment to worse outcomes, but this was driven by underlying disease severity.
  • After adjusting for adverse prognostic factors, a shorter diagnosis-to-treatment interval was significantly associated with improved overall survival.

A recent study published in Nature Health Sciences examined the relationship between the diagnosis-to-treatment interval (DTI) and survival outcomes in patients with diffuse large B-cell lymphoma (DLBCL). Led by researchers from institutions including the University of Canberra and Monash University, the investigation utilized data from the Lymphoma and Related Diseases Registry to evaluate 2,610 patients treated with immunochemotherapy. The findings help untangle how timing correlates with prognosis in aggressive malignancies.

The median DTI observed across the cohort was 15 days. Initial univariable analyses suggested that a shorter interval of 14 days or less was linked to worse overall survival and progression-free survival. However, the investigators noted that patients who began treatment quickly frequently presented with adverse clinical characteristics, such as advanced disease stages, poor performance status, and elevated lactate dehydrogenase levels. By applying causal inference methods—specifically inverse probability of treatment weighting—to adjust for these confounding severity factors, the researchers discovered that a shorter DTI was actually significantly associated with improved overall survival, yielding an adjusted hazard ratio of 0.68.

What to know: While prompt medical evaluation remains vital, the study suggests that rapid treatment initiation primarily serves as an indicator of advanced disease severity rather than being a negative prognostic factor in itself. Observational studies like this highlight the complexities of clinical data interpretation. Patients should consult their healthcare providers for personalized medical advice and care decisions.

Source Nature Health Sciences — nature.com/articles/s41598-026-78239-1 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.